Lilly present their continuous processing experience to IChemE and Engineers Ireland audience at CIT
Published on: Wednesday, 28 February 2018
Regina Lynch from Eli Lilly’s local plant in Dunderrow presented their experiences in developing continuous processing for API manufacture. This plant is now in production and has demonstrated the technical feasibility and advantages of manufacturing active pharmaceutical ingredients in a continuous process rather than the traditional batch approach. Continuous reactors are now Lilly’s preferred processing route for high hazard reactions e.g. hydrogenation, Grignard. Lowering the inventory in-process substantially reduces risk.
Regina explained the technical challenges that were overcome in developing equipment and practices that would successfully manufacture the desired products. The regulatory challenges are just as daunting: keeping track of inventory so as to have batch traceability is a major challenge involving extensive modelling and validation. The use of PAT including online HPLC are key facilitators of continuous API manufacture. The lecture concluded with a video walk-through of the building, showing the important layout considerations that were addressed. The audience of nearly 70 followed up with a series of probing questions which were very capably addressed by Regina.
Philip Roche making a presentation to Regina Lynch of Eli Lilly